|
|
Emerging evidence and scientific advancements are revealing pathophysiologic mechanisms correlated with systemic inflammation and the development of atherosclerotic cardiovascular disease (ASCVD). Patients with chronic kidney disease (CKD) are at high risk for developing ASCVD. Novel anti-inflammatory therapies are showing efficacy at reducing inflammation and development of ASCVD, and are adding to the treatment options beyond the usual lipid-lowering agents. As new clinical evidence and tar...
Integritas Communications
|
CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com
Terms of Service.
Site Map
